---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-012523"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2022-07-07T23:59:59+00:00"
generated_at: "2026-06-24T19:13:17.070829+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# KalVista FY2022 net loss $82.3M (-$3.36/share); cash $166.2M; sebetralstat Phase 3 on track

## Summary
- Net loss $82.3M ($3.36 loss per share) vs $46.2M ($2.42) prior year; R&D spend $70.2M.
- Cash & marketable securities $166.2M at April 30, 2022, down from $248.9M; funding into early 2024.
- Sebetralstat Phase 3 KONFIDENT trial enrollment on track; data expected H2 2023. EU orphan designation received.
- KVD824 Phase 2 KOMPLETE trial for HAE prevention on track; data expected mid-2023.
- Appointed Patrick A. Treanor (COO of Pathalys Pharma) to Board of Directors.

## SEC filing metadata
- accession: 0000950170-22-012523
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2022-07-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017022012523/0000950170-22-012523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017022012523/kalv-20220707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-012523
- JSON: https://secwatch.observer/filing/0000950170-22-012523.json
- Plain text: https://secwatch.observer/filing/0000950170-22-012523.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.